Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $110
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $95 to $110.
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $95 to $110.